Loading
A 2021 review of the pathways through which ivermectin killed cancer cells in the laboratory, written as a case for testing it in people.
The review, indexed as a systematic review, collects reports that ivermectin inhibits proliferation of several tumour cell types by regulating multiple signalling pathways and promotes programmed cell death, and discusses prospects for clinical use (Tang review 2021). The evidence it reviews is from cell lines and animal models (Tang review 2021).
Useful as a map of the laboratory story; it contains no patient outcomes.
Shares In vitro and in vivo, Systematic drug repurposing, Preclinical, Ivermectin.
Shares In vitro and in vivo, Preclinical, Ivermectin.
Shares In vitro and in vivo, Preclinical.
Shares Systematic drug repurposing, Ivermectin.
Shares Preclinical, Ivermectin.
Shares In vitro and in vivo, Preclinical.
Shares In vitro and in vivo, Preclinical, Ivermectin.
Shares Systematic drug repurposing, Ivermectin.